医药板块震荡上行，恒生创新药ETF（159316）、医药ETF（512010）受资金关注

Core Viewpoint - The pharmaceutical sector experienced a rise in indices, with significant inflows into related ETFs, indicating strong investor interest in the industry [1]. Group 1: Index Performance - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 0.7% [1]. - The CSI Innovative Drug Industry Index rose by 0.5% [1]. - The Hang Seng Hong Kong Stock Connect Innovative Drug Index and the CSI 300 Pharmaceutical and Health Index both saw an increase of 0.4% [1]. - The CSI Biotechnology Theme Index grew by 0.2% [1]. Group 2: Fund Inflows - The Hang Seng Innovative Drug ETF (159316) attracted approximately 400 million yuan in the past week [1]. - The Pharmaceutical ETF (512010) received around 900 million yuan in inflows during the same period [1]. Group 3: Index Composition and Valuation - The innovative drug index focuses on leading A-share companies involved in innovative drug research and development, comprising no more than 50 stocks [6]. - The rolling P/E ratio for the innovative drug index is currently 61.1 times [3]. - The biotechnology ETF tracks the CSI Biotechnology Theme Index, which includes up to 50 companies in gene diagnostics, biopharmaceuticals, and other biotechnology sectors, with a rolling P/E ratio of 57.8 times [8]. - The rolling P/E ratio for the CSI Innovative Drug Industry Index is 52.1 times [7].